Skip to content

OptimizeRx OPRX Impairment Charges

Impairment Charges at other companies

Cushman & Wakefield
 logo
Cushman & Wakefield CWK
$0-100%
DCH
Dauch CorporationDCH
$2M-33.3%
Harmonic logo
HarmonicHLIT
$409.25K-85.0%
Leslie's, Inc. logo
Leslie's, Inc.LESL
-$1.17M
MillerKnoll logo
MillerKnollMLKN
$0-100%
Medline, Inc.
 logo
Medline, Inc. MDLN
$0

Other financials

Income statement

See full
Revenue$19.8M-9.5%
Gross profit$14.9M+11.9%
Operating income$396.0K+119%
Net income-$495.0K+77.5%
EPS (diluted)-$0.03+75.0%

Balance sheet

See full
Cash & equivalents$20.2M+21.7%
Total debt$23.7M-27.7%
Total equity$129.6M+11.5%
Total assets$167.3M-0.3%

Cash flow

See full
Operating cash flow-$467.0K-112%
CapEx$21.0K-22.2%
Free cash flow-$488.0K-113%

Valuation

See full
Market cap$107.34M-54.1%
Enterprise value$110.88M-55.0%
P/E15.7×
P/S-1.2×

Profitability

See full
Gross margin70%+14.1pp
Operating margin13.2%
Net margin6.4%+3.6pp
FCF margin13.4%+4.8pp

Returns & leverage

See full
Return on equity5.6%+3.3pp
Debt / equity0.2×-0.1×
Current ratio5.4×+2.6×

Where this comes from

Reported directly by OptimizeRx in its filing.

Tagged under the XBRL concept oprx:ImpairmentCharges.

The official record: OptimizeRx’s 10-K, filed March 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about OptimizeRx's impairment charges.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is OptimizeRx's impairment charges?
OptimizeRx (OPRX) reported impairment charges of $92K in Q4 2025.
How has OptimizeRx's impairment charges changed year-over-year?
OptimizeRx's impairment charges decreased by 95.1% year-over-year, from $1.87M to $92K.
What does impairment charges mean?
This metric represents non-cash charges recognized when the carrying value of an asset, such as goodwill, intangible assets, or long-lived assets, exceeds its fair value. It serves as an indicator of potential overvaluation of assets or a decline in the expected future economic benefits of specific business units or investments. Investors monitor this to assess management's historical capital allocation decisions and the stability of the company's asset base.